Dr. Juan C. Ramos, MD

Dr. Ramos practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Ramos' NPI, 1215963145, was assigned on June 23, 2006. Dr. Ramos graduated from Rutgers New Jersey Medical School in 1999. Dr. Ramos holds Florida license ME88259.

Dr. Ramos' primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Ramos' primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Ramos is also affiliated with Jackson Memorial Hospital. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramos practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ramos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ramos is board certified in hematology by the American Board of Internal Medicine. Dr. Ramos is licensed in Florida.

Dmand AI lists chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Ramos treats.

CMS data shows 102 Medicare services from Dr. Ramos across 3 procedure codes in 2024, for 50 Medicare patients. Medicare paid $7,427 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 50 Medicare patients who saw Dr. Ramos in 2024. The largest group is 65 to 74, with 23 patients. 74% of them have high blood pressure, and 68% have high cholesterol. 56% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ramos' median patient age at 65, with 42% women.

In 2024, Dr. Ramos wrote 119 Medicare Part D claims for 25 patients. 88% of them were for generic drugs. CMS names the drug for 49 of them, across 2 drugs with 11 or more claims each, at $335 in total drug cost. In 2023, CMS named 102 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Ramos for performance year 2024, reported as part of a group. Dr. Ramos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ramos as offering telehealth.

Dmand AI links 40 papers to Dr. Ramos, published from 2007 to 2024. 2018 was the busiest year, with 5. The most frequent topics are Leukemia-Lymphoma, Adult T-Cell, Human T-lymphotropic virus 1 and Antineoplastic Combined Chemotherapy Protocols. Dr. Ramos has published most often in Blood. Dr. Ramos' most frequent co-authors are Lee Ratner, MD, Izidore Lossos, MD and Ariela Noy, MD.

Dmand AI links Dr. Ramos to 9 clinical trials, 4 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Sarcoma, Kaposi, AIDS-related Kaposi sarcoma and Anus Neoplasms. AIDS Malignancy Consortium sponsors the most, 4.

CMS Open Payments shows 37 general payments to Dr. Ramos from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 92% of the total. Acrotech Biopharma LLC paid the most, $13,708.

Dmand AI lists 1 award for Dr. Ramos, most recently CMS Stage 1 EHR in 2014.

Dr. Ramos graduated from Rutgers New Jersey Medical School in 1999.

Dr. Ramos is in network with 12 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 6. Check the plan with the practice before a visit.